

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 56546

Manuscript Type: ORIGINAL ARTICLE

Basic Study

Arachidyl amido cholanoic acid improves liver glucose and lipid homeostasis in nonalcoholic steatohepatitis *via* AMPK and mTOR regulation

Fernández-Ramos D *et al.* New mechanism of action of Aramchol

David Fernández-Ramos, Fernando Lopitz-Otsoa, Laura Delacruz-Villar, Jon Bilbao, Martina Pagano, Laura Mosca, Maider Bizkarguenaga, Marina Serrano-Macia, Mikel Azkargorta, Marta Iruarrizaga-Lejarreta, Jesús Sot, Darya Tsvirkun, Sebastiaan Martijn van Liempd, Felix M Goni, Cristina Alonso, María Luz Martínez-Chantar, Felix Elortza, Liat Hayardeny, **Shelly C Lu**, José M Mato

Abstract

Match Overview

Match Number	Source	Words	Similarity
1	Crossref	151 words Marta Iruarrizaga-Lejarreta, Marta Varela-Rey, David Fernández-Ramos, Ibon Martínez-Arranz et al. "Role of aran..."	3%
2	Internet	132 words crawled on 04-Jun-2019 www.galmedpharma.com	3%
3	Internet	102 words crawled on 12-Mar-2020 www.emjreviews.com	2%
4	Internet	87 words crawled on 14-Jul-2020 galmedpharma.investorroom.com	2%
5	Crossref	85 words Jorge Simon, Maitane Nuñez-García, Pablo Fernández-Tussy, Lucía Barbier-Torres et al. "Targeting Hepatic Gluta"	2%
6	Crossref Posted Content	72 words Aaron E. Robinson, Aleksandra Binek, Vidya Venkatraman, Brian C. Searle et al. "Quantitative Method for Assessin"	1%
7	Internet	65 words crawled on 07-Aug-2020 prod-journal.elifesciences.org	1%
8	Internet	56 words crawled on 10-Jan-2020 clinicaltrials.gov	1%

Aramchol improves liver glucose and lipid homeostasis



ALL

IMAGES

VIDEOS

92,900 Results

Any time ▾

[\[PDF\] galmedpharma.com](#)<https://galmedpharma.com/wp-content/uploads/2019/11/Aramchol-SCD1-inhibitor-improves...>

about **Aramchol improvement of NASH** and (**accumulation of lipids**, fibrosis traits lipotoxicity, oxidative stress and collagen production), indicating that **Aramchol stimulates glucose and fatty acid catabolism via AMPK pathway activation**, together with **reduction of gluconeogenesis and lipogenesis** through mTOR pathway inhibition.

Role of mTOR in Glucose and Lipid Metabolism

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073766>

Jul 13, 2018 · In this review, we provide a comprehensive summary on the **mTOR** signaling in the **regulation of glucose and lipid** metabolism. We will focus on the recent findings about the role of **mTOR** complex (mTORC) pathways in the **regulation** of energy balance and metabolism in key metabolic tissues, including adipose tissue, **liver**, skeletal muscle, pancreas ...

Cited by: 15**Author:** Zhuo Mao, Weizhen Zhang**Publish Year:** 2018

GLP-1 analogue improves hepatic lipid accumulation by ...

<https://www.sciencedirect.com/science/article/pii/S0006291X16307859>

GLP-1 analogue **improves** hepatic **lipid** accumulation by inducing autophagy **via AMPK/mTOR** pathway ... Effect of LRG on reducing BW and maintaining **glucose homeostasis** in C57BL ... Yuan, D. Wang, X. Ding, G. Liu, W. Li, X. Zhao, Z. Liu, Y. Li Hydrogen sulfide reduces serum triglyceride by activating **liver** autophagy **via** the **AMPK-mTOR** pathway. Am. J ...

Cited by: 67**Author:** Qin He, Sha Sha, Lei Sun, Jing Zhang, ...**Publish Year:** 2016

Treatment of nonalcoholic fatty liver disease: role of AMPK

<https://journals.physiology.org/doi/full/10.1152/ajpendo.00225.2016>

In these experiments, **glucose homeostasis** was improved and **liver lipid** content reduced by ~55%



52 Results Any time

New Data on Aramchol TM for the Treatment of Non-alcoholic ...

<https://www.emjreviews.com/hepatology/symposium/...>

Aramchol TM (arachidyl-amido cholanoic acid), ... Aramchol, a SCD1 Regulator, Improves Liver Glucose Homeostasis in NASH Professor José M. Mato. ... and activation of lipid droplet clearance, fatty acid oxidation, oxidative phosphorylation, antioxidant response, and the tricarboxylic acid (TCA) cycle was found in the analysis of 200 proteins ...

[PDF] New Data on AramcholTM for the Treatment of Non-alcoholic ...

<https://emj.emg-health.com/wp-content/uploads/...>

AramcholTM (arachidyl-amido cholanoic acid), a novel fatty acid bile acid conjugate, is currently being developed for the treatment of NASH and fibrosis. Aramchol is a liver-targeted, oral stearoyl coenzyme A desaturase 1 (SCD1) modulator that has been shown to reduce liver fat and fibrosis in patients with NASH in a Phase IIb clinical study

Pharmacological Activities of Alisma orientale against ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582889>

Jun 03, 2019 · 1. Introduction. Nonalcoholic fatty liver disease (NAFLD), a new challenge of chronic liver disease in the 21 st century, includes simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. A recent meta-analysis reported that global prevalence of NAFLD was assessed to be 25.24% [], and its prevalence is likely to increase up to 33.5% in adults by 2030 [].

Cited by: 4 Author: Eunsol Choi, Eungyeong Jang, Jang-Hoon ...

Publish Year: 2019

Challenges and opportunities in drug development for ...

<https://www.sciencedirect.com/science/article/pii/S0014299920300054>

Mar 05, 2020 · Aramchol (arachidyl amido cholanoic acid: SCD-1 modulator: N = 2000, NASH, NAS ≥ 4, fibrosis stage 2 or 3: 52 wks: Resolution of NASH or improvement in fibrosis by 1 stage and no worsening of NASH: All-cause mortality, liver transplantation, histological progression, MELD score > 15 hospitalization: NCT03900429: Resmetirom (MGL-3196) THR-β ...

Cited by: 1 Author: Matthias Ocker

Publish Year: 2020

Therapeutic Landscape for NAFLD in 2020 - ScienceDirect

<https://www.sciencedirect.com/science/article/pii/S0016508520302225>

May 01, 2020 · The bile salt-fatty acid conjugate Aramchol (arachidyl amido cholanoic acid) was found to have inhibitory effects on SCD in mouse studies and demonstrated a protective effect against NAFLD, which could be mediated by AMPK-induced oxidative disposal rather than SCD inhibition. 151 An early clinical trial of Aramchol in patients with NAFLD ...

Cited by: 2 Author: Brent A. Neuschwander-Tetri

Publish Year: 2020

Pharmacological Activities of Alisma orientale against ...

<https://www.hindawi.com/journals/ecam/2019/2943162>

Nonalcoholic fatty liver disease (NAFLD) is a rapidly emerging hepatic manifestation of metabolic syndrome. However, its unrevealed mechanism and complicated comorbidities have led to no specific medication, except for weight loss and lifestyle modification. Alisma orientale (Sam.) Juzep (A. orientale , Alismataceae) has been increasingly reported on therapeutic effects of A. orientalei ...

Search Tools

Turn off Hover Translation (关闭取词)



54 Results Any time ▾

New Data on Aramchol TM for the Treatment of Non-alcoholic ...

<https://www.emjreviews.com/hepatology/symposium/...>

Aramchol TM (**arachidyl-amido cholanoic acid**), ... Aramchol, a SCD1 Regulator, **Improves Liver Glucose Homeostasis** in NASH Professor José M. Mato. ... and activation of **lipid** droplet clearance, fatty **acid** oxidation, oxidative phosphorylation, antioxidant response, and the tricarboxylic **acid** (TCA) cycle was found in the analysis of 200 proteins ...

Challenges and opportunities in drug development for ...

<https://www.sciencedirect.com/science/article/pii/S0014299920300054>

Mar 05, 2020 · Aramchol (**arachidyl amido cholanoic acid**: SCD-1 modulator: N = 2000, NASH, NAS ≥ 4, fibrosis stage 2 or 3: 52 wks: Resolution of NASH or improvement in fibrosis by 1 stage and no worsening of NASH: All-cause mortality, **liver** transplantation, histological progression, MELD score > 15 hospitalization: NCT03900429: Resmetirom (MGL-3196) THR-β ...

Cited by: 1 **Author:** Matthias Ocker

Publish Year: 2020

Pharmacological Activities of *Alisma orientale* against ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582889>

Jun 03, 2019 · 1. Introduction. **Nonalcoholic** fatty **liver** disease (NAFLD), a new challenge of chronic **liver** disease in the 21 st century, includes simple steatosis, **nonalcoholic steatohepatitis** (NASH), fibrosis, and cirrhosis. A recent meta-analysis reported that global prevalence of NAFLD was assessed to be 25.24% [], and its prevalence is likely to increase up to 33.5% in adults by 2030 [].

Cited by: 4 **Author:** Eunsol Choi, Eungyeong Jang, Jang-Hoo...

Publish Year: 2019

[PDF] HEPATOLOGY

<https://galmedpharma.com/wp-content/uploads/2020/...>

AramcholTM (**arachidyl-amido cholanoic acid**), a novel fatty **acid** bile **acid** conjugate, is currently being developed for the treatment of NASH and fibrosis. Aramchol is a **liver**-targeted, oral stearoyl coenzyme A desaturase 1 (SCD1) modulator that has been shown to reduce **liver** fat and fibrosis in patients with NASH in a Phase IIb clinical study